donanemab
AssetAntibody
Monoclonal antibody targeting N3pG-beta-amyloid to promote clearance of amyloid plaques.
- Stage
- Approved
- Modality
- Antibody
- Target
- APP
- Indications
- 17
- Trials
- 16
- Developers
- 1
Indications
17Alzheimer's disease
Approvedaccessdata.fda.gov7 Oct 2026
Amyloid pathology
Approvedema.europa.eu7 Oct 2026
Cognitive dysfunction
Approvedema.europa.eu7 Oct 2026
14 more
- Targets and what it contains2
- Owner and partners1
- Trials16
- Evidence for its targets2
- Competitors12
- Aging relevance1
- Signals5
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 11 sources